Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quinapril · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Quinapril Hydrochloride Tablets 40 mg |
| 2 | ACTIVE_COMPARATOR | Accupril® Tablets 40 mg |
| Name | Type | Description |
|---|---|---|
| Quinapril Hydrochloride Tablets 40 mg | DRUG | 40mg, single dose fasting |
| Accupril® Tablets 40 mg | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to e...
Quinapril is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with completed trials evaluating its pharmacokinetics under fasting and fed conditions. The drug is being developed by Viatris Inc. and is not yet approved for any indication.
Quinapril is being developed by Viatris Inc., a company traded on the NASDAQ under the ticker VTRS. The drug is currently in Phase 1 clinical development, with two completed trials in healthy volunteers. Viatris is responsible for the ongoing research and potential commercialization of this investigational product.
Quinapril is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers in the United States. The drug remains investigational and has not received FDA approval. Further clinical studies would be needed to advance it to later stages of development.
Quinapril has two completed Phase 1 clinical trials. NCT00649103 is a fasting study comparing Quinapril Hydrochloride Tablets 40 mg to Accupril Tablets 40 mg, enrolling 60 participants. NCT00649649 is a food study with the same comparison, enrolling 24 participants. Both trials were conducted in the United States with healthy volunteers aged 18 years and older.
Quinapril is being studied as a generic version of Accupril, which is the brand-name reference drug. The clinical trials compare Quinapril Hydrochloride Tablets 40 mg to Accupril Tablets 40 mg to assess bioequivalence. Quinapril is an investigational product, while Accupril is the established brand-name medication.